The Burn Glove Trial - Hand Burn Dressing Pilot

Sponsor
Southern Illinois University (Other)
Overall Status
Withdrawn
CT.gov ID
NCT02318056
Collaborator
(none)
0
1
3
7
0

Study Details

Study Description

Brief Summary

Specific Aim 1: To determine if one of three burn dressings provides a less painful healing experience for partial thickness hand.

Specific Aim 2: To evaluate if one of three dressings provides greater functionality during and after healing of partial thickness hand burns.

Specific Aim 3: To determine if one of three burn dressings promotes aesthetically superior healing results for partial thickness hand burns.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Various products are on the market and available for use on partial thickness burns to the hand/s. Our current institutional standard of care is to use Xeroform Gauze (Coviden, Mansfield, MA) and Bacitracin Ointment (Fougera, Melville, NY) to promote a moist antibacterial healing environment with the ability to monitor the healing progress daily. However, silver (AG) based dressings that employ nanocrystalline technology with hydrofiber (Aquacel AG burn; ConvaTec, Princeton, NJ) or soft silicone foam (Mepilex AG ; Molnlycke Health Care, Dunstable, United Kingdom) have been well accepted as alternative dressing solutions. These dressings have longer interval times between changes, leading to a reported increase in patient comfort, diminished skin shearing/stripping, and rapid re-epithelialization.

Given the anatomic intricacies, partial thickness burns to the hand present a challenge in dressing selection. Recently, ConvaTec unveiled the Aquacel AG Burn Glove for use on partial thickness hand burns. In line with this idea, our institution has now begun to fashion a novel burn glove out of Mepilex Transfer AG with good success. To date there are no known studies that compare Xeroform/Bacitracin, Aquacel AG burn glove or Mepilex Transfer AG dressing. The goal of this study is to compare these three burn dressings used to treat partial-thickness hand burns and their impact on pain, function, and aesthetic outcomes. We will also explore psychosocial issues related to hand burn dressing changes.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Burn Glove Trial-A Randomized Controlled Trial of Dressings for Partial Thickness Hand Burns
Study Start Date :
Dec 1, 2015
Actual Primary Completion Date :
Jul 1, 2016
Actual Study Completion Date :
Jul 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Aquacel® Ag Burn Glove

Application of Aquacel® Ag Burn Glove burn dressing

Other: Aquacel® Ag Burn Glove
burn dressing
Other Names:
  • ConvaTec
  • Active Comparator: Mepilex® Transfer Ag

    Application of Mepilex® Transfer Ag burn dressing

    Other: Mepilex® Transfer Ag
    burn dressing
    Other Names:
  • Safetac®
  • Molnlycke® Health Care
  • Active Comparator: Xeroform®/Bacitracin®

    Application of Xeroform® burn dressing and Bacitracin® topical antibiotic

    Drug: antibiotic
    antibiotic burn dressing
    Other Names:
  • Bacitracin®
  • Xeroform®
  • Outcome Measures

    Primary Outcome Measures

    1. pain [baseline to 6 months post-burn injury]

      pain as measured by the Patient and Provider Scar Assessment Scale

    Secondary Outcome Measures

    1. pain [baseline to 6 months post-burn injury]

      pain as measured by the Michigan Hand Outcomes Questionnaire (MHQ)

    2. pain [baseline to 6 months post-burn injury]

      pain as measured by the Disabilities of the Arm, Shoulder and Hand Scale, Quick (QuickDASH)

    3. functionality [baseline to 6 months post-burn injury]

      functionality as measured by the Michigan Hand Outcomes Questionnaire (MHQ)

    4. functionality [baseline to 6 months post-burn injury]

      functionality as measured by the Disabilities of the Arm, Shoulder and Hand Scale, Quick (QuickDASH)

    5. aesthetic appearance [baseline to 6 months post-burn injury]

      scar formation and aesthetic appearance measured using the Vancouver Scar Scale

    6. aesthetic appearance [baseline to 6 months post-burn injury]

      scar formation and aesthetic appearance measured using the the Patient and Provider Scar Assessment Scale

    Other Outcome Measures

    1. quality of life [baseline to 6 months post-burn injury]

      quality of life measured by the psychosocial scales: Burn Specific Health Scale (BSHS)

    2. resilience [baseline to 6 months post-burn injury]

      resilience measured by the Connor-Davidson Resilience Scale (CD-RISC)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    8 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients presenting at Memorial Medical or Southern Illinois University (SIU) Health Care

    • Patients with partial-thickness burn injuries to the dorsum and/or palm of the hand/s that exceeds ½% total body surface area (TBSA) for at least one hand.

    • < 10% TBSA 2nd and 3rd degree burn injuries

    • Initial clinical presentation < 5 days post burn injury

    Exclusion Criteria:
    • < ½ % TBSA involving the hand

    • 10%TBSA burn injuries

    • 60 years of age

    • < 8 years of age

    • Patients (or parents of minors) without cognitive capacity to comprehend informed consent

    • Presentation > 5 days post-burn injury event

    • Pregnant women

    • Full thickness/3rd degree burns to the dorsal and/or palmer hand/s

    • Exposed vital structures (tendons, nerves, bone, vessels)

    • Uncontrolled Type II Diabetes

    • Type I Diabetes

    • History of Chronic Obstructive Pulmonary Disease

    • Have a known allergy to silver products

    • Signs of infection on initial clinical presentation (presence of purulent drainage, significant cellulitis, and/or fever)

    • Smoke/inhalation injuries requiring ventilation

    • Critically ill patients requiring intensive care

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Southern Illinois University School of Medicine Springfield Illinois United States 62794-9640

    Sponsors and Collaborators

    • Southern Illinois University

    Investigators

    • Principal Investigator: Nada N Berry, MD, Southern Illinois University

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Southern Illinois University
    ClinicalTrials.gov Identifier:
    NCT02318056
    Other Study ID Numbers:
    • ABR-SIUSOM-14-002
    First Posted:
    Dec 17, 2014
    Last Update Posted:
    Jul 21, 2016
    Last Verified:
    Jul 1, 2016
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Southern Illinois University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 21, 2016